Compare NWCLW & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWCLW | CTNM |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 504.3M | 550.7M |
| IPO Year | N/A | 2024 |
| Metric | NWCLW | CTNM |
|---|---|---|
| Price | $0.75 | $12.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | N/A | ★ 457.5K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $8.60 |
| 52 Week High | N/A | $17.79 |
| Indicator | NWCLW | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 38.81 |
| Support Level | N/A | $11.73 |
| Resistance Level | N/A | $13.54 |
| Average True Range (ATR) | 0.00 | 0.91 |
| MACD | 0.00 | -0.21 |
| Stochastic Oscillator | 0.00 | 38.63 |
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.